Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "Institute"

868 News Found

Medica, Kolkata and UNICEF collaborate to empower working mothers
News | August 03, 2023

Medica, Kolkata and UNICEF collaborate to empower working mothers

Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop


Upsurge in pink eye conjunctivitis cases in the country
Healthcare | July 29, 2023

Upsurge in pink eye conjunctivitis cases in the country

Take proper precautions and seek timely treatment!


Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer
News | July 28, 2023

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference


Novartis acquires DTx Pharma to develop siRNA therapies
News | July 19, 2023

Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications


Sun Pharma presents data from Phase 1 studies of GL0034
News | June 26, 2023

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity


LVPEI raises awareness on antimicrobial resistance among medical students
News | June 23, 2023

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety


Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
interviews | June 20, 2023

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma